نتائج البحث

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.

• Authors : Kahraman S; Ankara Bilkent City Hospital, Department Of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, 06800, Turkey. .; Hizal M

Subjects: Cyclin-Dependent Kinase 4*/Cyclin-Dependent Kinase 4*/Cyclin-Dependent Kinase 4*/antagonists & inhibitors ; Cyclin-Dependent Kinase 6*/Cyclin-Dependent Kinase 6*/Cyclin-Dependent Kinase 6*/antagonists & inhibitors ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy

• Source: BMC cancer [BMC Cancer] 2024 Dec 30; Vol. 24 (1), pp. 1592. Date of Electronic Publication: 2024 Dec 30.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway.

• Authors : Huang Z; The Second Surgical Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Lou K

Subjects: Purines*/Purines*/Purines*/pharmacology ; Purines*/Purines*/Purines*/therapeutic use ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy

• Source: Journal of translational medicine [J Transl Med] 2024 Nov 22; Vol. 22 (1), pp. 1052. Date of Electronic Publication: 2024 Nov 22.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

HIF-1α-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma.

• Authors : Geng P; State Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, Liaoning Province, 116023, China.; Liaoning Province Key Laboratory of Metabolomics, Dalian, Liaoning Province, 116023, China.

Subjects: ErbB Receptors*/ErbB Receptors*/ErbB Receptors*/metabolism ; ErbB Receptors*/ErbB Receptors*/ErbB Receptors*/genetics ; Gefitinib*/Gefitinib*/Gefitinib*/pharmacology

• Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Sep 30; Vol. 43 (1), pp. 269. Date of Electronic Publication: 2024 Sep 30.Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.

• Authors : Dajsakdipon T; Susiriwatananont T ...

Subjects: Piperazines*/Piperazines*/Piperazines*/administration & dosage ; Piperazines*/Piperazines*/Piperazines*/adverse effects ; Piperazines*/Piperazines*/Piperazines*/therapeutic use

• Source: BMC cancer [BMC Cancer] 2024 Aug 16; Vol. 24 (1), pp. 1018. Date of Electronic Publication: 2024 Aug 16.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

De novo engineering riboflavin production Bacillus subtilis by overexpressing the downstream genes in the purine biosynthesis pathway.

• Authors : Liu C; Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, China.; Key Laboratory of Engineering Biology for Low-Carbon Manufacturing, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 West 7th Avenue, Tianjin Airport Economic Area, Tianjin, 300308, China.

Subjects: Riboflavin*/Riboflavin*/Riboflavin*/biosynthesis ; Riboflavin*/Riboflavin*/Riboflavin*/metabolism ; Bacillus subtilis*/Bacillus subtilis*/Bacillus subtilis*/genetics

• Source: Microbial cell factories [Microb Cell Fact] 2024 May 31; Vol. 23 (1), pp. 159. Date of Electronic Publication: 2024 May 31.Publisher: BioMed Central Country of Publication: England NLM ID: 101139812 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Integrated network pharmacology and metabolomics to reveal the mechanism of Pinellia ternata inhibiting non-small cell lung cancer cells.

• Authors : Feng, Fan¹ (AUTHOR); Hu, Ping¹ (AUTHOR); Peng, Lei¹ (AUTHOR)

Subjects: *THERAPEUTIC use of antineoplastic agents; *CELL migration inhibition; *WOUND healingCHINA

• Source: BMC Complementary Medicine & Therapies. 7/11/2024, Vol. 24 Issue 1, p1-16. 16p.

تفاصيل العنوان

Stretches of alternating pyrimidine/purines and purines are respectively linked with pathogenicity and growth temperature in prokaryotes.

• Authors : Bohlin, Jon^1,2 ; Hardy, Simon P.¹ ; Ussery, David W.³

• Source: BMC Genomics. 2009, Vol. 10, p346-353. 8p. 2 Charts, 4 Graphs.

تفاصيل العنوان

Association between dietary approaches to stop hypertension (DASH) diet and hyperuricemia among Chinese adults: findings from a nationwide representative study.

• Authors : Zhu, Qianrang¹; Yu, Lianlong^2,3; Li, Yuqian^1,2

Subjects: *DASH diet; *URIC acid; *PURINES

• Source: Nutrition Journal. 3/29/2023, Vol. 22 Issue 1, p1-10. 10p.

تفاصيل العنوان

Transcriptome-aligned metabolic profiling by SERSome reflects biological changes following mesenchymal stem cells expansion.

• Authors : Bi, Xinyuan; Ma, Bin; Liu, Wei

Subjects: SERS spectroscopy; MESENCHYMAL stem cells; BIOMOLECULES

• Source: Stem Cell Research & Therapy; 12/18/2024, Vol. 15 Issue 1, p1-14, 14p

تفاصيل العنوان

First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report.

• Authors : Pangarsa EA; Hematology Medical Oncology Division, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital Semarang, Semarang, Indonesia.; Elisabeth Hospital Semarang, Semarang, Indonesia.

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/pathology ; Cyclin-Dependent Kinase 4*/Cyclin-Dependent Kinase 4*/Cyclin-Dependent Kinase 4*/antagonists & inhibitors

• Source: Journal of medical case reports [J Med Case Rep] 2024 Dec 05; Vol. 18 (1), pp. 591. Date of Electronic Publication: 2024 Dec 05.Publisher: BioMed Central Country of Publication: England NLM ID: 101293382 Publication Model: Electronic Cited Medium:

تفاصيل العنوان